0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Diagnostic Accuracy of the Amsler Grid Test for Detecting Neovascular Age-Related Macular Degeneration : A Systematic Review and Meta-analysis

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Importance

          Patients with nonneovascular age-related macular degeneration (AMD) are encouraged to use the Amsler grid test for self-assessment to facilitate early diagnosis. The test is widely recommended, suggesting a belief that it signals worsening AMD, warranting its use in home monitoring.

          Objective

          To systematically review studies of the diagnostic test accuracy of the Amsler grid in the diagnosis of neovascular AMD and to perform diagnostic test accuracy meta-analyses.

          Data Sources

          A systematic literature search was conducted in 12 databases for relevant titles from database inception until May 7, 2022.

          Study Selection

          Studies included those with groups defined as having (1) neovascular AMD and (2) either healthy eyes or eyes with nonneovascular AMD. The index test was the Amsler grid. The reference standard was ophthalmic examination. After removal of obviously irrelevant reports, 2 authors (J.B. and M.S.) independently screened the remaining references in full text for potential eligibility. Disagreements were resolved by a third author (Y.S.).

          Data Extraction and Synthesis

          Two authors (J.B. and I.P.) independently extracted all data and evaluated quality and applicability of eligible studies using the Quality Assessment of Diagnostic Accuracy Studies 2. Disagreements were resolved by a third author (Y.S.).

          Main Outcomes and Measures

          Sensitivity and specificity of the Amsler grid for detecting neovascular AMD with comparators being either healthy control participants or patients with nonneovascular AMD.

          Results

          Of 523 records screened, 10 studies were included with a total of 1890 eyes (mean participant age ranging from 62 to 83 years). Sensitivity and specificity to diagnose neovascular AMD were 67% (95% CI, 51%-79%) and 99% (95% CI, 85%-100%), respectively, when comparators were healthy control participants and 71% (95% CI, 60%-80%) and 63% (95% CI, 49%-51%), respectively, when control participants were patients with nonneovascular AMD. Overall, potential sources of bias were low across studies.

          Conclusions and Relevance

          Although the Amsler grid is easy and inexpensive to use for detection of metamorphopsia, its sensitivity may be at levels typically not recommended for monitoring. Coupling this lower sensitivity with only moderate specificity to identify neovascular AMD in a population at risk, these findings suggest that such patients typically should be encouraged to undergo ophthalmic examination regularly, regardless of any results of Amsler grid self-assessment.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.

          In 2003, the QUADAS tool for systematic reviews of diagnostic accuracy studies was developed. Experience, anecdotal reports, and feedback suggested areas for improvement; therefore, QUADAS-2 was developed. This tool comprises 4 domains: patient selection, index test, reference standard, and flow and timing. Each domain is assessed in terms of risk of bias, and the first 3 domains are also assessed in terms of concerns regarding applicability. Signalling questions are included to help judge risk of bias. The QUADAS-2 tool is applied in 4 phases: summarize the review question, tailor the tool and produce review-specific guidance, construct a flow diagram for the primary study, and judge bias and applicability. This tool will allow for more transparent rating of bias and applicability of primary diagnostic accuracy studies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies

            Systematic reviews of diagnostic test accuracy synthesize data from primary diagnostic studies that have evaluated the accuracy of 1 or more index tests against a reference standard, provide estimates of test performance, allow comparisons of the accuracy of different tests, and facilitate the identification of sources of variability in test accuracy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010.

              To report incidence rates of legal blindness from age-related macular degeneration (AMD) and other causes in Denmark from years 2000 to 2010 in the age group at risk of AMD aged 50 years and older. Population-based observational registry study. settings: Membership register of the Danish Association of the Blind, the primary admission criterion of which is best-corrected visual acuity 0.1 (20/200) or lower in a person's better-seeing eye. study population: A total of 11 848 incident cases of legal blindness from a population of citizens aged ≥50 years numbering 1.71 million in 2000 and 1.87 million in 2010 with free access to a single-payer public health care system. main outcome measures: Incidence rates of legal blindness from AMD from 2000 to 2010. The incidence rate of legal blindness attributable to AMD in citizens aged ≥50 years decreased from 52.2 cases per year per 100 000 in 2000 to 25.7 cases per year per 100 000 in 2010, corresponding to a reduction of 50% (95% confidence interval [CI(95)]: 45%-56%, P < .0001, adjusted for age), the bulk of the reduction occurring after 2006. The incidence of legal blindness from causes other than AMD decreased by 33% (CI(95): 21%-44%, P < .0001), most of the reduction occurring between 2000 and 2006. From 2000 to 2010 the incidence of legal blindness from AMD fell to half the baseline incidence. The bulk of the reduction occurred after the introduction of intravitreally injected inhibitors of vascular endothelial growth factor in 2006. Copyright © 2012 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Journal
                JAMA Ophthalmology
                JAMA Ophthalmol
                American Medical Association (AMA)
                2168-6165
                February 16 2023
                Affiliations
                [1 ]Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark
                [2 ]Department of Ophthalmology, Semmelweis University, Budapest, Hungary
                [3 ]Department of Ophthalmology, Leiden University Medical Centre, Leiden, the Netherlands
                [4 ]Department of Ophthalmology, Haga Hospital, The Hague, the Netherlands
                [5 ]Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
                [6 ]Department of Ophthalmology, Odense University Hospital, Odense, Denmark
                [7 ]Department of Clinical Research, University of Southern Denmark, Odense, Denmark
                [8 ]Department of Ophthalmology, Vestfold Hospital Trust, Tønsberg, Norway
                [9 ]Department of Ophthalmology, University Hospital Bonn, Bonn, Germany
                [10 ]Department of Ophthalmology, University Hospital Basel, Basel, Switzerland
                [11 ]National Institute for Health and Care Research Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and University College London Institute of Ophthalmology, London, United Kingdom
                [12 ]MitØje Aps, Skive, Denmark
                [13 ]Department of Ophthalmology, Kütahya Health Sciences University, Evliya Celebi Training and Research Hospital, Kütahya, Turkey
                Article
                10.1001/jamaophthalmol.2022.6396
                36795396
                0c0b6cdb-b50e-4e17-b499-5869669642f1
                © 2023
                History

                Comments

                Comment on this article